Strategies for developing dual-targeted soluble epoxide hydrolase inhibitors

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Drug Discovery

Background:

• Soluble epoxide hydrolase (sEH) regulates epoxyeicosatrienoic acids (EETs), impacting metabolic, cardiovascular, cerebrovascular, inflammatory, and pain pathways.
• sEH is a validated therapeutic target, but single-target inhibitors face limitations in efficacy and resistance for complex diseases.
• Multi-target drug discovery, particularly dual-target inhibitors, presents a promising strategy to overcome these challenges.

Purpose of the Study:

• To systematically review the research progress of dual-target sEH inhibitors.
• To analyze the rational design, structure-activity relationship (SAR) optimization, and translational prospects of these ligands.
• To provide a foundation for developing improved multi-target sEH therapeutic strategies.

Main Methods:

• Literature review of studies on dual-target sEH inhibitors.
• Analysis of drug design principles and SAR data for sEH ligands.
• Evaluation of in vivo efficacy and safety data for dual-target agents.

Main Results:

• Dual-target sEH inhibitors demonstrate synergistic pathway modulation, enhancing therapeutic efficacy and reducing resistance.
• These inhibitors show improved in vivo efficacy and safety profiles compared to single-target agents.
• Evidence supports the potential of dual-target sEH inhibitors for various complex diseases.

Conclusions:

• Dual-target sEH inhibitors represent a significant advancement over single-target approaches.
• Further research into rational design and SAR optimization is crucial for clinical translation.
• These strategies hold promise for developing more effective and safer treatments for a range of disorders.